Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

T cell receptor identifying PRAME antigenic short-peptide

A cell receptor, cell technology, applied in the field of TCR, can solve problems such as normal cell damage

Active Publication Date: 2017-05-24
XLIFESC LTD
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For the treatment of the above diseases, methods such as chemotherapy and radiotherapy can be used, but all of them will cause damage to their own normal cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • T cell receptor identifying PRAME antigenic short-peptide
  • T cell receptor identifying PRAME antigenic short-peptide
  • T cell receptor identifying PRAME antigenic short-peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0144] Example 1 Cloning of PRAME Antigen Short Peptide-Specific T Cells

[0145] Peripheral blood lymphocytes (PBL) from healthy volunteers with genotype HLA-A2402 were stimulated with the synthetic short peptide PYLGQMINL (SEQ ID NO.9; Beijing Saibaisheng Gene Technology Co., Ltd.). The PYLGQMINL short peptide was annealed with biotin-labeled HLA-A2402 to prepare pHLA haploids. These haploids were combined with PE-labeled streptavidin (BD Company) to form PE-labeled tetramers, and the tetramers and anti-CD8-APC double-positive cells were sorted. Sorted cells were expanded and subjected to secondary sorting as described above, followed by monoclonalization by limiting dilution. Monoclonal cells were stained with tetramers, and the double-positive clones screened were as follows: image 3 shown.

Embodiment 2

[0146] Example 2 Obtaining the construction of TCR gene and carrier of PRAME antigen short peptide-specific T cell clone

[0147] with Quick-RNA TM MiniPrep (ZYMO research) extracted the total RNA of the short antigenic peptide PYLGQMINL-specific and HLA-A2402-restricted T cell clones screened in Example 1. The cDNA was synthesized using clontech's SMART RACE cDNA amplification kit, and the primers used were designed at the C-terminal conserved region of the human TCR gene. The sequence was cloned into T vector (TAKARA) for sequencing. It should be noted that this sequence is complementary and does not contain introns. After sequencing, the sequence structures of the TCR α chain and β chain expressed by the double-positive clone are shown in Figure 1 and Figure 2, respectively. Figure 1a , Figure 1b , Figure 1c , Figure 1d , Figure 1e with Figure 1f They are the amino acid sequence of TCRα chain variable domain, the nucleotide sequence of TCRα chain variable doma...

Embodiment 3

[0157] Example 3 Expression, refolding and purification of PRAME antigen short peptide-specific soluble TCR

[0158] In order to obtain a soluble TCR molecule, the α and β chains of the TCR molecule of the present invention may only include their variable domains and part of the constant domains respectively, and a cysteine ​​residue is introduced into the constant domains of the α and β chains respectively To form an artificial interchain disulfide bond, the positions of the introduced cysteine ​​residues are Thr48 of TRAC*01 exon 1 and Ser57 of TRBC2*01 exon 1; the amino acid sequence and nucleotides of the α chain sequence as Figure 4a with Figure 4b As shown, the amino acid sequence and nucleotide sequence of its β chain are as follows Figure 5a with Figure 5b The introduced cysteine ​​residues are shown in bold and underlined letters. The target gene sequences of the above TCRα and β chains were synthesized and inserted into the expression vector pET28a+ (Novagene...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a T cell receptor (TCR) capable of specifically combining short-peptide PYLGQMINL derived from a PRAME antigen, and the antigenic short-peptide PYLGQMINL and HLA A2402 can form a compound and are together delivered to the cell surface. The invention further provides nucleic acid molecules encoding the TCR and a carrier comprising the nucleic acid molecules. The invention further provides a cell transducing the TCR.

Description

technical field [0001] The present invention relates to TCRs capable of recognizing short peptides derived from PRAME antigens. The present invention also relates to PRAME-specific T cells obtained by transducing the above TCRs, and their use in the prevention and treatment of PRAME-related diseases. Background technique [0002] PRAME is a preferentially expressed antigen of melanoma (PRAME), which is expressed in 88% of primary and 95% of metastatic melanoma (Ikeda H, etal. Immunity, 1997, 6(2): 199-208) , normal skin tissue and benign melanocytes are not expressed. After PRAME is produced in cells, it is degraded into small molecular polypeptides, and combines with MHC (major histocompatibility complex) molecules to form a complex, which is presented to the cell surface. PYLGQMINL, a short peptide derived from the PRAME antigen, is a target for the treatment of PRAME-associated diseases. In addition to melanoma, PRAME is also expressed in a variety of tumors, including ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/725C12N15/12C12N15/867C12N5/10A61K38/17A61K35/17A61P37/02A61P35/00A61P35/02
CPCA61K35/17A61K38/00C07K14/70503
Inventor 李懿林燕梅相瑞瑞
Owner XLIFESC LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com